Zacks Research Has Positive Forecast for BHC Q2 Earnings

Bausch Health Companies Inc. (NYSE:BHC) – Analysts at Zacks Research raised their Q2 2025 earnings estimates for Bausch Health Companies in a research report issued on Tuesday, December 17th. Zacks Research analyst R. Department now expects that the company will post earnings per share of $1.03 for the quarter, up from their prior forecast of $1.00. The consensus estimate for Bausch Health Companies’ current full-year earnings is $3.74 per share. Zacks Research also issued estimates for Bausch Health Companies’ FY2025 earnings at $4.28 EPS, Q1 2026 earnings at $1.09 EPS, Q2 2026 earnings at $1.14 EPS, Q3 2026 earnings at $1.37 EPS and FY2026 earnings at $5.05 EPS.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Wednesday, October 30th. The company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.10. The firm had revenue of $2.51 billion during the quarter, compared to analyst estimates of $2.42 billion. Bausch Health Companies had a negative net margin of 1.88% and a negative return on equity of 755.86%. The business’s revenue was up 12.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.03 EPS.

Other research analysts have also issued reports about the company. Royal Bank of Canada upped their price target on Bausch Health Companies from $10.00 to $11.00 and gave the stock a “sector perform” rating in a report on Friday, November 1st. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Friday, October 25th. Finally, Evercore ISI upgraded shares of Bausch Health Companies to a “hold” rating in a research report on Tuesday, October 15th. One research analyst has rated the stock with a sell rating, five have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $7.75.

Bausch Health Companies Stock Up 0.7 %

Shares of NYSE:BHC opened at $7.39 on Thursday. The company has a market cap of $2.67 billion, a price-to-earnings ratio of -15.40 and a beta of 0.69. The business has a 50 day moving average price of $8.35 and a 200 day moving average price of $7.27. Bausch Health Companies has a twelve month low of $3.96 and a twelve month high of $11.46.

Hedge Funds Weigh In On Bausch Health Companies

A number of hedge funds and other institutional investors have recently made changes to their positions in BHC. Headlands Technologies LLC acquired a new position in Bausch Health Companies in the second quarter worth about $35,000. MQS Management LLC acquired a new position in shares of Bausch Health Companies in the 2nd quarter worth approximately $71,000. Certuity LLC bought a new position in shares of Bausch Health Companies during the 2nd quarter worth approximately $75,000. Bfsg LLC boosted its stake in Bausch Health Companies by 46.7% in the 2nd quarter. Bfsg LLC now owns 11,450 shares of the company’s stock valued at $80,000 after buying an additional 3,643 shares in the last quarter. Finally, Kendall Capital Management bought a new stake in Bausch Health Companies in the second quarter valued at $87,000. 78.65% of the stock is owned by institutional investors.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.